Bradley Merrill Thompson, Member of the Firm in the Health Care and Life Sciences practice, in the firm’s Washington, DC, office, was quoted in MobiHealthNews, in “FDA Finalizes Plans to Deregulate MDDS Health Software,” by Brian Dolan.
Following is an excerpt:
“Now FDA has exempted the software from all FDA regulation, and indeed swept in image management software,” Epstein Becker’s Brad Thompson told MobiHealthNews in an email. “The implications are profound, both for MDDS type software, but also for what it suggests about the future for health information technology generally. FDA is quite earnestly working to ensure that it uses the lightest regulatory touch appropriate for software.”